炎症因子在多发性骨髓瘤早期复发中的预测价值
The Predictive Value of Inflammatory Factors in the Early Recurrence of Multiple Myeloma
DOI: 10.12677/acm.2025.15102790, PDF,   
作者: 李海涛:昆明医科大学第三附属医院医学检验科,云南 昆明
关键词: 多发性骨髓瘤炎症因子早期复发预测模型Multiple Myeloma Inflammatory Factors Early Recurrence Prediction Model
摘要: 多发性骨髓瘤是一种具有高复发率和耐药风险的浆细胞恶性肿瘤,传统预测体系虽提供一定指导,但在动态监测和敏感性方面仍显不足。炎症因子因其在肿瘤微环境调控、免疫逃逸和耐药机制中的作用,逐渐成为复发预测研究的关键。本文聚焦IL-6、TNF-α、IL-1β、IL-17、IL-10与IFN-γ等核心炎症因子,系统探讨其在疾病进程中的功能,分析其与复发风险的关联、联合构建预测模型的价值,以及与现有体系的互补潜力。基于当前研究,炎症因子希望成为实现MM早期复发风险识别与精准干预的重要工具。
Abstract: Multiple myeloma is a malignant plasma cell tumor with high recurrence rate and drug resistance risk. Although the traditional prediction system provides certain guidance, it still falls short in dynamic monitoring and sensitivity. Inflammatory factors, due to their roles in regulating the tumor microenvironment, immune escape, and drug resistance mechanisms, have gradually become the key for recurrence prediction research. This paper focuses on core inflammatory factors such as IL-6, TNF-α, IL-1β, IL-17, IL-10, and IFN-γ, systematically explores their functions in the disease process, analyzes their association with the risk of recurrence, the value of jointly constructing prediction models, and the complementary potential with existing systems. Based on current research, inflammatory factors are expected to become an important tool for identifying the early recurrence risk and achieving precise intervention in MM.
文章引用:李海涛. 炎症因子在多发性骨髓瘤早期复发中的预测价值[J]. 临床医学进展, 2025, 15(10): 555-561. https://doi.org/10.12677/acm.2025.15102790

参考文献

[1] Menachem, R., Nudelman, I., Vorontsova, A., Livneh, I., Sela, M., Benguigui, M., et al. (2025) Bone Marrow-Targeted Liposomes Loaded with Bortezomib Overcome Multiple Myeloma Resistance. ACS Nano, 19, 11684-11701. [Google Scholar] [CrossRef] [PubMed]
[2] Ni, W., Garg, S., Chowdhury, B., Sattler, M., Sanchez, D., Meng, C., et al. (2025) Dual Carm1-and Ikzf3-Targeting: A Novel Approach to Multiple Myeloma Therapy between CARM1 Inhibition and IMiDs. Molecular Therapy Oncology, 33, Article 200952. [Google Scholar] [CrossRef] [PubMed]
[3] Malek, E., Rana, P.S., Swamydas, M., Daunov, M., Miyagi, M., Murphy, E., et al. (2023) Vactosertib, a Novel TGFB Type I Receptor Kinase Inhibitor, Improves T-Cell Fitness: A Single-Arm, Phase 1b Trial in Relapsed/Refractory Multiple Myeloma. Blood, 142, 4749-4749. [Google Scholar] [CrossRef
[4] Guliyev, M., Tunc, A., Yılmaz, U., Kucukyurt, S., Ozmen, D., Elverdi, T., et al. (2025) Extramedullary Disease in Multiple Myeloma at Diagnosis and over the Course of the Disease. International Journal of Hematology, 122, 73-82. [Google Scholar] [CrossRef] [PubMed]
[5] Chawla, Y., Anderson, E.I., Smith, M., Jain, S., Evans, L.A., Neff, J., et al. (2025) Lactate Metabolism in Clonal Plasma Cells and Its Therapeutic Implications in Multiple Myeloma Patients with Elevated Serum LDH Levels. Cancer & Metabolism, 13, 389-390. [Google Scholar] [CrossRef] [PubMed]
[6] Carr, N.J., Haslam, A. and Prasad, V. (2025) Financial Conflicts among Physician Speakers at the April 12, 2024 Oncology Drug Advisory Meeting: Who Decided That MRD Can Be a Novel Regulatory Endpoint in Myeloma? Journal of Cancer Policy, 43, Article 100529. [Google Scholar] [CrossRef] [PubMed]
[7] Martinez-Lopez, J., Lopez-Muñoz, N., Chari, A., Dorado, S., Barrio, S., Arora, S., et al. (2024) Measurable Residual Disease (MRD) Dynamics in Multiple Myeloma and the Influence of Clonal Diversity Analyzed by Artificial Intelligence. Blood Cancer Journal, 14, 562-564. [Google Scholar] [CrossRef] [PubMed]
[8] Tie, W., Ma, T., Liu, J., Yi, Z., Xiong, H., Bai, J., et al. (2025) Visfatin Promotes Multiple Myeloma Cell Proliferation and Inhibits Apoptosis by Inducing IL-6 Production via NF-κB Pathways. Discover Oncology, 16, 650-652. [Google Scholar] [CrossRef] [PubMed]
[9] Kuroki, W., Kitadate, A., Takahashi, Y., Iwama, S., Yamada, M., Kobayashi, T., et al. (2025) Multiple Myeloma with 1q Gain/Amplification Exhibits Reduced CD38 Expression via Interleukin‐6 Receptor Overexpression. British Journal of Haematology, 206, 1615-1626. [Google Scholar] [CrossRef] [PubMed]
[10] Yucel, E.E., Ozsan, G.H., Togay, A., Oztur, O.C., Yuksel, F., Yilmaz, N., Olgun, A. and Alacacioglu, I. (2025) Impact of Pre-Transplant Serum Levels of Activin A, Activin B, IGF-1 and IL-6 on Transplant Outcomes and Survival in Patients with Multiple Myeloma: A Prospective Study. European Review for Medical and Pharmacological Sciences, 29, 45-46.
[11] Mazurek, M., Szudy-Szczyrek, A., Homa-Mlak, I., Hus, M., Małecka-Massalska, T. and Mlak, R. (2024) IL1B Polymorphism (rs1143634) and IL-1β Plasma Concentration as Predictors of Nutritional Disorders and Prognostic Factors in Multiple Myeloma Patients. Cancers, 16, Article 1263. [Google Scholar] [CrossRef] [PubMed]
[12] 刘琳, 聂鼎睿, 安超, 孙玲. 多发性骨髓瘤患者血清EPO、IL-6、TNF-α、IL-1β水平及其与贫血的相关性分析[J].河南医学研究, 2021, 30(8): 1369-1373.
[13] Jeyaraju, D.V., Kumari, E., Amatangelo, M., Bjorklund, C.C., Hsu, C. and Thakurta, A. (2019) ZFP91 Regulates Multiple Myeloma Cell Proliferation through IL-1β Mediated IL-6 Secretion in the Tumor Microenvironment. Blood, 134, 4406-4406. [Google Scholar] [CrossRef
[14] 陆萍, 费小明, 汤郁, 叶炜, 颜玲玲, 朱彦. IL-1β和TNF-α通过骨髓MSCs降低多西环素对骨髓瘤细胞株H929的细胞毒性作用[J]. 南京医科大学学报(自然科学版), 2018, 38(4): 470-475.
[15] Rossi, M., Altomare, E., Botta, C., Gallo Cantafio, M.E., Sarvide, S., Caracciolo, D., et al. (2020) MiR-21 Antagonism Abrogates Th17 Tumor Promoting Functions in Multiple Myeloma. Leukemia, 35, 823-834. [Google Scholar] [CrossRef] [PubMed]
[16] Leipold, A.M., Werner, R.A., Düll, J., Jung, P., John, M., Stanojkovska, E., et al. (2023) Th17.1 Cell Driven Sarcoidosis-Like Inflammation after Anti-BCMA CAR T Cells in Multiple Myeloma. Leukemia, 37, 650-658. [Google Scholar] [CrossRef] [PubMed]
[17] Fernandes, Q., Ansari, A.W., Makni-Maalej, K., Merhi, M., Dermime, S., Ahmad, A., et al. (2025) Interleukin 10: Bridging the Chasms in the Immune Landscape of Multiple Myeloma. In: International Review of Cell and Molecular Biology, Elsevier, 199-222. [Google Scholar] [CrossRef] [PubMed]
[18] Ostanin, A.A., Batorova, D.S., Sizikova, S.A. and Krukovich, A.B. (2024) Экспрессия чек-поинт-молекул популяциями регуляторных Т-клеток при множественной миеломе. Медицинская иммунология, 26, 913-918. [Google Scholar] [CrossRef
[19] Minnie, S.A., Waltner, O.G., Zhang, P., Takahashi, S., Nemychenkov, N.S., Ensbey, K.S., et al. (2024) TIM-3+ CD8 T Cells with a Terminally Exhausted Phenotype Retain Functional Capacity in Hematological Malignancies. Science Immunology, 9, 77-79. [Google Scholar] [CrossRef] [PubMed]
[20] Yuti, P., Sawasdee, N., Natungnuy, K., Rujirachaivej, P., Luangwattananun, P., Sujjitjoon, J., et al. (2023) Enhanced Antitumor Efficacy, Proliferative Capacity, and Alleviation of T Cell Exhaustion by Fifth-Generation Chimeric Antigen Receptor T Cells Targeting B Cell Maturation Antigen in Multiple Myeloma. Biomedicine & Pharmacotherapy, 168, Article 115691. [Google Scholar] [CrossRef] [PubMed]
[21] 张婷, 刘佳栋. 外周血淋巴细胞亚群、IL-6、PCT的表达水平对胃癌术后复发的预测价值研究[J]. 国际检验医学杂志, 2025, 31(4): 288-291.
[22] Cao, J., Hu, B., Li, T., Fang, D., Jiang, l. and Wang, J. (2025) Cellular Heterogeneity and Cytokine Signatures in Acute Myeloid Leukemia: A Novel Prognostic Model. Translational Oncology, 52, Article 102194. [Google Scholar] [CrossRef] [PubMed]
[23] Jafari-Raddani, F., Davoodi-Moghaddam, Z. and Bashash, D. (2024) Construction of Immune-Related Gene Pairs Signature to Predict the Overall Survival of Multiple Myeloma Patients Based on Whole Bone Marrow Gene Expression Profiling. Molecular Genetics and Genomics, 299, 446-449. [Google Scholar] [CrossRef] [PubMed]
[24] Mian, H., Seow, H., Balitsky, A. K., et al. (2025) A Prognostic Symptom Model Incorporating Patient-Reported Symptoms for Transplant-Ineligible Patients with Multiple Myeloma. Cancers, 17, Article 489. [Google Scholar] [CrossRef] [PubMed]
[25] Elmeliegy, M., Viqueira, A., Vandendries, E., Hickman, A., Conte, U., Irby, D., et al. (2025) Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple Myeloma. Targeted Oncology, 20, 349-359. [Google Scholar] [CrossRef] [PubMed]
[26] Jasrotia, S., Gupta, R., Sharma, A., Halder, A. and Kumar, L. (2020) Cytokine Profile in Multiple Myeloma. Cytokine, 136, Article 155271. [Google Scholar] [CrossRef] [PubMed]